Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".

Takahashi H, Anzai K

DOI: 10.1002/hep4.1996
Published: 2022 Sep
Container: Hepatology communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/hep4.1996,
  title = {Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".},
  author = {Takahashi H and Anzai K},
  year = {2022},
  journal = {Hepatology communications},
  doi = {10.1002/hep4.1996},
  url = {https://doi.org/10.1002/hep4.1996}
}

RIS

TY  - JOUR
TI  - Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
AU  - Takahashi H
AU  - Anzai K
PY  - 2022
JO  - Hepatology communications
DO  - 10.1002/hep4.1996
UR  - https://doi.org/10.1002/hep4.1996
ER  -

APA

H, T., & K, A. (2022). Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".. Hepatology communications. https://doi.org/10.1002/hep4.1996

Source records

pubmed · retrieved 2026-09-25T12:57:39.523Z